NCT06938321View on ClinicalTrials.gov

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Biliary Tract Cancer
Interventions
DRUG

AK112

Following a predefined dose and date.

DRUG

AK130

Following a predefined dose and date.

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT06938321 - A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter